Proellex

A Safety and Pharmacokinetic Study of Proellex®

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

Crossover Study of the Safety and PK Properties of Proellex®

Study to Evaluate Menses Induction in Women Administered Proellex

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

Determination of the Lowest, Safe and Effective Dose of Proellex

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Open-Label Extension Study to ZPE-202

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids